Pulmonic regurgitation epidemiology and demographics: Difference between revisions
Jump to navigation
Jump to search
| Line 21: | Line 21: | ||
===Age=== | ===Age=== | ||
*[[Patients]] of all [[age]] groups may [[Development|develop]] [[pulmonic regurgitation]] (PR) depending on the etiology. | |||
*In the U.S population, the prevalence of [[valvular heart disease]] is higher in older adults.<ref name="urlValvular Heart Disease | cdc.gov">{{cite web |url=https://www.cdc.gov/heartdisease/valvular_disease.htm |title=Valvular Heart Disease | cdc.gov |format= |work= |accessdate=}}</ref> | *In the U.S population, the prevalence of [[valvular heart disease]] is higher in older adults.<ref name="urlValvular Heart Disease | cdc.gov">{{cite web |url=https://www.cdc.gov/heartdisease/valvular_disease.htm |title=Valvular Heart Disease | cdc.gov |format= |work= |accessdate=}}</ref> | ||
*[[ | * In 1989, a meta‐analysis reported that 29% of the [[patients]] with isolated congenital [[PR]] develop symptoms within 40 years. The risk of development of symptoms demonstrated an increase with age, particularly after 40 years.<ref name="ShimazakiBlackstone2008">{{cite journal|last1=Shimazaki|first1=Y.|last2=Blackstone|first2=E.|last3=Kirklin|first3=J.|title=The Natural History of Isolated Congenital Pulmonary Valve Incompetence: Surgical Implications|journal=The Thoracic and Cardiovascular Surgeon|volume=32|issue=04|year=2008|pages=257–259|issn=0171-6425|doi=10.1055/s-2007-1023399}}</ref> | ||
*In 1990, the incidence of mild degree valvular regurgitation in normal subjects was estimated to increase with [[age]].<ref name="pmid2310593">{{cite journal| author=Klein AL, Burstow DJ, Tajik AJ, Zachariah PK, Taliercio CP, Taylor CL et al.| title=Age-related prevalence of valvular regurgitation in normal subjects: a comprehensive color flow examination of 118 volunteers. | journal=J Am Soc Echocardiogr | year= 1990 | volume= 3 | issue= 1 | pages= 54-63 | pmid=2310593 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2310593 }} </ref> | *In 1990, the incidence of mild degree valvular regurgitation in normal subjects was estimated to increase with [[age]].<ref name="pmid2310593">{{cite journal| author=Klein AL, Burstow DJ, Tajik AJ, Zachariah PK, Taliercio CP, Taylor CL et al.| title=Age-related prevalence of valvular regurgitation in normal subjects: a comprehensive color flow examination of 118 volunteers. | journal=J Am Soc Echocardiogr | year= 1990 | volume= 3 | issue= 1 | pages= 54-63 | pmid=2310593 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2310593 }} </ref> | ||
| Line 33: | Line 33: | ||
===Developed Countries=== | ===Developed Countries=== | ||
*In developed countries such as the United States, [[PAH|Pulmonary hypertension]] (PAH) is primarily due to left heart disease. Other conditions that cause [[PAH]] include [[sickle cell disease]]; [[pulmonary embolus]], and [[chronic obstructive pulmonary disease]] (COPD).<ref name="urlPulmonary Hypertension | NHLBI, NIH">{{cite web |url=https://www.nhlbi.nih.gov/health-topics/pulmonary-hypertension#:~:text=In%20the%20United%20States%2C%20the,obstructive%20pulmonary%20disease%20(COPD). |title=Pulmonary Hypertension | NHLBI, NIH |format= |work= |accessdate=}}</ref> | |||
*[[Rheumatic heart disease]] (RHD) is not a common cause of [[PAH]] or [[PR]] in developed countries. Due to the early detection and development of treatment strategies [[RHD]] is rare in developed countries.<ref name="pmid25076991">{{cite journal |vauthors=Bhagavatula SK, Idrees MM |title=Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Challenges in managing pulmonary hypertension in the developing countries |journal=Ann Thorac Med |volume=9 |issue=Suppl 1 |pages=S127–30 |date=July 2014 |pmid=25076991 |pmc=4114281 |doi=10.4103/1817-1737.134059 |url=}}</ref><ref name="VaideeswarButany2016">{{cite journal|last1=Vaideeswar|first1=P.|last2=Butany|first2=J.|title=Valvular Heart Disease|year=2016|pages=485–528|doi=10.1016/B978-0-12-420219-1.00012-4}}</ref> | |||
===Developing Countries=== | ===Developing Countries=== | ||
* In developing countries | *In developing countries [[PAH|Pulmonary hypertension]] (PAH) is primarily due to [[rheumatic heart disease]] (RHD), [[schistosomiasis]], [[congenital heart disease]], [[hemolytic diseases]]. [[PAH]] is a major cause of secondary [[PR]]. The burden of [[PAH]] is greater in developing than developed countries.<ref name="pmid25076991">{{cite journal |vauthors=Bhagavatula SK, Idrees MM |title=Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Challenges in managing pulmonary hypertension in the developing countries |journal=Ann Thorac Med |volume=9 |issue=Suppl 1 |pages=S127–30 |date=July 2014 |pmid=25076991 |pmc=4114281 |doi=10.4103/1817-1737.134059 |url=}}</ref><ref name="ButrousGhofrani2008">{{cite journal|last1=Butrous|first1=Ghazwan|last2=Ghofrani|first2=Hossein Ardeschir|last3=Grimminger|first3=Friedrich|title=Pulmonary Vascular Disease in the Developing World|journal=Circulation|volume=118|issue=17|year=2008|pages=1758–1766|issn=0009-7322|doi=10.1161/CIRCULATIONAHA.107.727289}}</ref> | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
Revision as of 05:57, 2 August 2020
|
Pulmonic regurgitation Microchapters |
|
Diagnosis |
|---|
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Aravind Kuchkuntla, M.B.B.S[2], Aysha Anwar, M.B.B.S[3]
Overview
The prevalence of mild pulmonary regurgutation is present in 40% to 78% of patients with normal pulmonary valve anatomy.[1][2] There is increased prevalence of pulmonary regurgitation with increasing age.
Epidemiology and Demographics
Prevalence
- The prevalence of valvular heart disease in U.S. population is estimated to be 2.5%. About 13% of U.S population born before 1943 have valvular heart disease.[3]
- The prevalence of mild PR is present in 40% to 78% of patients with normal pulmonary valve anatomy.[4][2][5]
- In 1987, the prevalence of PR in patients with structurally normal hearts was estimated to be 5% in Boston area population, USA.[1]
- In 1990, the prevalence of PR in normal patients (21 - 82 years) was estimated to be 31%.[5]
- In 1992, the prevalence of PR in children (birth- 14 years) with structurally normal hearts was estimated to be 21.9% in Jerusalem, Israel population. Pulmonic regurgitation was the most common of all valvular regurgitations detected among children.[6]
Incidence
- In patients born with congenital heart disease, 20% of patients have associated abnormalities of the pulmonary valve or the right ventricular outlet obstruction.[1]
Case-fatality rate/Mortality rate
- According to CDC, in 2017 24% of deaths due to valvular heart disease were attributed to tricuspid valve and pulmonic valve abnormalities combined.[3]
Age
- Patients of all age groups may develop pulmonic regurgitation (PR) depending on the etiology.
- In the U.S population, the prevalence of valvular heart disease is higher in older adults.[3]
- In 1989, a meta‐analysis reported that 29% of the patients with isolated congenital PR develop symptoms within 40 years. The risk of development of symptoms demonstrated an increase with age, particularly after 40 years.[7]
- In 1990, the incidence of mild degree valvular regurgitation in normal subjects was estimated to increase with age.[5]
Race
- There is no racial or ethnic predilection for pulmonary regurgitation.
Gender
- The prevalence and incidence of PR does not vary by gender.
Developed Countries
- In developed countries such as the United States, Pulmonary hypertension (PAH) is primarily due to left heart disease. Other conditions that cause PAH include sickle cell disease; pulmonary embolus, and chronic obstructive pulmonary disease (COPD).[8]
- Rheumatic heart disease (RHD) is not a common cause of PAH or PR in developed countries. Due to the early detection and development of treatment strategies RHD is rare in developed countries.[9][10]
Developing Countries
- In developing countries Pulmonary hypertension (PAH) is primarily due to rheumatic heart disease (RHD), schistosomiasis, congenital heart disease, hemolytic diseases. PAH is a major cause of secondary PR. The burden of PAH is greater in developing than developed countries.[9][11]
References
- ↑ 1.0 1.1 1.2 Choong CY, Abascal VM, Weyman J, Levine RA, Gentile F, Thomas JD; et al. (1989). "Prevalence of valvular regurgitation by Doppler echocardiography in patients with structurally normal hearts by two-dimensional echocardiography". Am Heart J. 117 (3): 636–42. PMID 2784023.
- ↑ 2.0 2.1 Takao S, Miyatake K, Izumi S, Okamoto M, Kinoshita N, Nakagawa H; et al. (1988). "Clinical implications of pulmonary regurgitation in healthy individuals: detection by cross sectional pulsed Doppler echocardiography". Br Heart J. 59 (5): 542–50. PMC 1276894. PMID 3382565.
- ↑ 3.0 3.1 3.2 "Valvular Heart Disease | cdc.gov".
- ↑ Zoghbi, William A.; Adams, David; Bonow, Robert O.; Enriquez-Sarano, Maurice; Foster, Elyse; Grayburn, Paul A.; Hahn, Rebecca T.; Han, Yuchi; Hung, Judy; Lang, Roberto M.; Little, Stephen H.; Shah, Dipan J.; Shernan, Stanton; Thavendiranathan, Paaladinesh; Thomas, James D.; Weissman, Neil J. (2017). "Recommendations for Noninvasive Evaluation of Native Valvular Regurgitation". Journal of the American Society of Echocardiography. 30 (4): 303–371. doi:10.1016/j.echo.2017.01.007. ISSN 0894-7317.
- ↑ 5.0 5.1 5.2 Klein AL, Burstow DJ, Tajik AJ, Zachariah PK, Taliercio CP, Taylor CL; et al. (1990). "Age-related prevalence of valvular regurgitation in normal subjects: a comprehensive color flow examination of 118 volunteers". J Am Soc Echocardiogr. 3 (1): 54–63. PMID 2310593.
- ↑ Brand, Abraham; Dollberg, Shaul; Keren, Andre (1992). "The prevalence of valvular regurgitation in children with structurally normal hearts: A color Doppler echocardiographic study". American Heart Journal. 123 (1): 177–180. doi:10.1016/0002-8703(92)90763-L. ISSN 0002-8703.
- ↑ Shimazaki, Y.; Blackstone, E.; Kirklin, J. (2008). "The Natural History of Isolated Congenital Pulmonary Valve Incompetence: Surgical Implications". The Thoracic and Cardiovascular Surgeon. 32 (04): 257–259. doi:10.1055/s-2007-1023399. ISSN 0171-6425.
- ↑ "Pulmonary Hypertension | NHLBI, NIH".
- ↑ 9.0 9.1 Bhagavatula SK, Idrees MM (July 2014). "Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Challenges in managing pulmonary hypertension in the developing countries". Ann Thorac Med. 9 (Suppl 1): S127–30. doi:10.4103/1817-1737.134059. PMC 4114281. PMID 25076991.
- ↑ Vaideeswar, P.; Butany, J. (2016). "Valvular Heart Disease": 485–528. doi:10.1016/B978-0-12-420219-1.00012-4.
- ↑ Butrous, Ghazwan; Ghofrani, Hossein Ardeschir; Grimminger, Friedrich (2008). "Pulmonary Vascular Disease in the Developing World". Circulation. 118 (17): 1758–1766. doi:10.1161/CIRCULATIONAHA.107.727289. ISSN 0009-7322.